Quantum Genomics Société Anonyme announced the enrollment of the first patient in the Company’s REFRESH study (Randomized study of Extended treatment with Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partners DongWha for South-Korea and Orient Europharma for South-East-Asia, Australia and New Zeland. This multicenter, multinational study will enroll 750 patients with difficult-to-treat2 or resistant3 hypertension in 96 study sites in Europe, Canada, US, Taiwan, and South-Korea. For the first double-blind randomized three-month period, 750 patients will receive firibastat (1000mg once-a-day) or placebo, on top of their current therapy. The primary endpoint will be reduction in systolic automated office blood pressure (AOBP) from baseline. After this first period, subjects will be treated and followed-up for six additional months (and 12 months for 100 patients) to assess long-term safety, data that are mandatory for New Drug Application (NDA) for a chronic treatment. Efficacy results and six-month safety results – that will support the New Drug Application - are expected for mid-2023.